Today announced that it offers initiated a new Phase III trial designed to evaluate the efficacy.

‘We believe pimavanserin has an ideal profile to successfully deal with PDP without impairing motor function and, therefore, supplies the potential for an important progress in therapy for patients suffering from this large unmet medical need.’.. ACADIA initiates new pimavanserinContinue reading… Today announced that it offers initiated a new Phase III trial designed to evaluate the efficacy.

Seung-Jung Park.

Cohen, M.D., Alan C. Yeung, M.D., Seung Ho Hur, M.D., Ki Bae Seung, M.D., Tae Hoon Ahn, M.D., Hyuck Moon Kwon, M.D., Do-Sunlight Lim, M.D., Seung-Woon Rha, M.D., Myung-Ho Jeong, M.D., Bong-Ki Lee, M.D., Damras Tresukosol, M.D., Guo Sheng Fu,Continue reading… Seung-Jung Park.